Farmingham, CT - A new mouse study published this week provides some insight into understanding why rofecoxib (Vioxx, Merck) and the other cyclooxygenase (COX)-2 inhibitors increase the risk of ...
Anti-inflammatory drugs have long served as a cornerstone in the treatment of conditions marked by inflammation, pain, and fever. At the heart of many of these therapeutic agents lies the inhibition ...
The recent withdrawal of rofecoxib (Vioxx) from the market has intensified controversy about the safety of cyclooxygenase (COX)-2 inhibitors. Results from several recently published studies address ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results